

Cancer Registrars Association of the Dakotas

2026 Annual Educational Conference



Hybrid Conference

**THURSDAY & FRIDAY,
SEPTEMBER 10-11, 2026**

Sanford Center Coyote Room

2301 E 60th St N

Sioux Falls, SD 57104

605-312-6571

8.25 CEIP hours of which 6.25 hours meet the *Category A* requirement. Event Number: 2026-196IP.

CRAD contact: wendy.trucke@sanfordhealth.org or (605) 310-5261



Thursday, September 10, 2026

8:00 am.....	Welcome – CRAD 2026 President	Jessi Lehn, ODS-C
8:15 am.....	HPV-Associated Oropharynx & STRs	Denise Harrison, ODS-C
10:00 am.....	Break	
10:15 am.....	Hematopoietic Malignancies	Jennifer Ruhl, M.S., CCS, RHIT, ODS-C
11:15 am.....	Prostate Cancer - Overview of Staging, SSDIs and TURP Issues	Amanda Degroot, ODS-C, RHIT
12:00 pm.....	Lunch	
1:00 pm.....	Stop Asking Whether AI Will Replace Registrars: Start Asking What Registry Work Should Look Like Next	Michele Webb, ODS-C
2:15 pm.....	Personalizing Gynecologic Cancer Care: How Biomarkers, Immunotherapy and Targeted Therapies are Changing Practice	Dr. Luis Rojas
3:15 pm.....	Break	
3:30 pm.....	CRAD Business Meeting	
4:30 pm.....	Announcements/Housekeeping	

Friday, September 11, 2026

8:00 am.....	Welcome – CRAD President	Jessi Lehn, ODS-C
8:15 am.....	Perils of Abstracting	Melissa Riddle, ODS-C
9:15 am.....	Pharmacogenomics in Cancer Care	April Schultz, PharmD
10:15 am.....	Break	

10:30 am..... From Family History to Genomic Medicine:
An Introduction to Cancer Genetics Rebecca Loman, CGC

11:30 am..... Completion of Business Meeting/Installation of New Officers

12:00 pm..... Feedback/Farewell

Conference Objectives:

- Emphasize the importance of using the most current version of the STR manual as soon as it is released.
- Discuss when it is appropriate to apply the STR for mets.
- Demonstrate how to calculate the interval for the timing rules.
- Show changes effective with the 2026 Update to the STR Manual (new format of the histology tables, determining multiple primaries, coding histology). Showing examples of scenarios and how to apply the rules correctly.
- Highlight AJCC, EOD, and Summary Stage changes between 8th Edition and V9 for HPV-associated oropharyngeal cancers. Review the anatomy and regional lymph nodes.
- Reinforce information using case scenarios and polls.
- Discuss and assign AJCC TNM categories and prognostic stage groups, including classification timeframes.
- Explain and assign the SSDIs and Grade fields, SEER Summary Stage 2018 and EOD fields including changes for V9.
- Learn and understand the basic techniques and rules on how to assign primary site for Hematopoietic neoplasms.
- Comprehend the updated rules for assigning histology for Hematopoietic neoplasms and apply the multiple primary rules correctly.
- Understand common errors made while coding Grade and how to correctly assign Grade.
- Accurately assign difficult SSDIs for specific sites such as lung (separate tumor nodules), prostate (counting cores), breast (ER/PR ranges), etc.
- Gain knowledge in coding surgery of the primary site codes.

- Explain why the future of cancer registry work should be evaluated beyond the question of AI replacing Registrars.
- Distinguish task automation from comprehensive registry workflow redesign.
- Describe how the registrar's role may evolve as routine tasks become increasingly automated.
- Identify higher-value work and responsibilities for registry professionals in an AI-enabled environment.
- Evaluate whether automation delivers meaningful value to the registry, its workforce and the organization.
- Describe key biomarkers in gynecologic cancers (e.g., MMR, HDR, FRα, PD-L1) and their role in guiding treatment selection.
- Review recent evidence supporting the integration of immunotherapy and antibody drug conjugates into endometrial, ovarian and cervical cancer management.
- Identify practical implications of emerging therapies on multidisciplinary oncology care including patient selection, sequencing and toxicity management.
- Understand common errors made while coding grade and how to correctly assign grade.
- Accurately assign difficult SSDIs for specific sites such as lung (separate tumor nodules), prostate (counting cores), breast (ER/PR ranges), etc.
- Gain knowledge in coding surgery of the primary site codes.
- Define Pharmacogenomics (PGx). Describe the benefits and limitations of PGx.
- Identify clinical use cases for PGx in cancer care.
- Goals and process of genetic counseling and testing, including the role of genetic counselors in patient care.
- Basic genetic concepts including genes, variants and commonly used tumor markers relevant to cancer diagnosis and management.
- Difference between germline and somatic genetic testing.
- Identify red flags in the personal and family history that may suggest an inherited cancer predisposition syndrome.
- Participants will have an understanding of clinical staging for prostate cancer looking at Clinical T – DRE, Blank vs. X and, imaging. Review recent updates for SSDIs: PSA and Cores Positive and Examined. Discuss prostate TURP issue – incidental diagnosis of cancer with active surveillance recommendation.